A life-long treatment for high LDL, a VESALIUS subanalysis, tirzepatide beats semaglutide again, arrhythmia burden in cardiac amyloidosis, and a lipid guideline rebuttal are the topics John Mandrola, MD, discusses in this week’s podcast.
John M. Mandrola
Geo Focus
Coverage Attributes:
Beta
Informative:
46
%
Data Driven:
23
%
Promotional:
19
%
Interviews Q&as:
2
%
Opinion:
2
%
Themes Covered:
Not enough data
Most Recent Topics:
Not enough data
Pitching Insights
John M. Mandrola's coverage heavily focuses on cardiology, medical updates, healthcare, research, and heart health. His articles often include announcements and cite data with a significant portion dedicated to expert commentary.
Given the high percentage of expert commentary in his coverage attributes, John would likely be interested in receiving pitches from experts in the field of cardiology who can provide insightful analysis or comment on recent medical developments or studies within the cardiovascular space.
As a prominent figure covering healthcare and pharmaceutical topics with an emphasis on cardiology, he may also be receptive to timely pitches related to emerging treatments or groundbreaking research within this field.
This information evolves through artificial intelligence and human feedback. Improve this profile .
Journalists With Similar Coverage:
Based on similarity of content.
Publications
Most recent topics
Not enough data
Publications
Most recent topics
Not enough data
Publications
Most recent topics
Not enough data
